A5091753510- Sarcoma Diagnosis and Treatment
- Urologic and reproductive health conditions
- Cancer Genomics and Diagnostics
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Vascular Tumors and Angiosarcomas
- Ovarian cancer diagnosis and treatment
- Cancer Treatment and Pharmacology
- Prostate Cancer Treatment and Research
- Testicular diseases and treatments
- Inflammatory Biomarkers in Disease Prognosis
- Urological Disorders and Treatments
- Urinary and Genital Oncology Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cardiac tumors and thrombi
- Lymphoma Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- BRCA gene mutations in cancer
- Breast Cancer Treatment Studies
- Prostate Cancer Diagnosis and Treatment
- Bladder and Urothelial Cancer Treatments
- Lung Cancer Treatments and Mutations
- Genomic variations and chromosomal abnormalities
- IgG4-Related and Inflammatory Diseases
- Chemokine receptors and signaling
Tokyo National Hospital
2017-2025
National Cancer Center
2012-2024
National Cancer Center Hospital East
2014-2023
Kurashiki Central Hospital
2011
Triple-negative breast cancer (TNBC) is negative for hormone receptors and human epidermal growth factor receptor 2 (HER2). In stage I TNBC, adjuvant therapy or follow-up are performed according to risk factors, but clinical trial data scarce. recent years, it has been reported that HER2-low cases (1+/2+ in situ hybridization negative) have different prognoses than HER2-0 cases. However, the of recurrence factors this population TNBC not yet investigated.Herein, out 174 patients with who...
Introduction: Next-generation sequencing (NGS) is commonly used in clinical practice to decide treatment based on genomic information. This study was performed optimize the proportion of actionable gene profiling and genetic alterations breast cancer at one centers Japan. Methods: Patients with who reported NGS results Japan from August 2019 December 2023 were retrospectively investigated by reviewing their electronic medical records. examined using OncoGuideTM NCC Oncopanel System,...
<title>Abstract</title> Background This study aimed to identify prognostic factors at the time of first recurrence retroperitoneal liposarcoma (LPS). Methods The medical records 150 patients who underwent tumor resection for primary LPS our institute were reviewed. Among 94 experienced recurrence, including both local and distal recurrent treatment patterns retrospectively analyzed. Results Tumor resection, radiation therapy, chemotherapy performed in 41, 12, 23 patients, respectively,...
Abstract Background: Ovarian clear cell carcinoma (OCCC) is a rare subtype of ovarian cancer, with higher incidence in East Asia compared to Western countries and tendency affect younger individuals. OCCC has poor prognosis due its low sensitivity chemotherapy, presenting significant unmet medical need. However, therapeutic development been limited rarity. Recently, advancements antibody-drug conjugates (ADCs) targeting Trophoblastic cell-surface marker (TROP2) have shown promise, but the...
ABSTRACT Objective To compare the survival outcomes of de‐escalation chemotherapy with those standard first‐line in patients International Germ Cell Cancer Collaborative Group (IGCCCG) good prognosis metastatic seminoma. Methods The cohort this retrospective, observational, single‐center study comprised 35 clinical Stage I (CSI)‐relapsed or de novo IGCCCG seminoma who had undergone induction at our institution between 2007 and 2021. Patients were allocated to therapy groups according average...
ABSTRACT Background Adenoid cystic carcinoma (ACC) is the second most common and treatment‐resistant salivary gland (SGC). Although platinum‐based therapies are effective, efficacy of eribulin, a microtubule inhibitor with an 18% response rate in Phase II trial involving recurrent/metastatic SGC, patients advanced ACC after platinum therapy remains unclear. Methods We retrospectively analyzed 19 unresectable/metastatic treated between December 2015 January 2023 at National Cancer Center...
•Of 507 patients who underwent CGP, 12.2% received genomically matched therapies with a 32.3% ORR.•The PFS ratios (>1.3) were observed in 46.3% (19/41) of the evaluated patients.•Patients rare cancers benefited most from tumor mutation profiling.•Early-line treatments following profiling increase therapeutic benefit, irrespective type. BackgroundComprehensive genome (CGP) serves as guide for suitable cancer. However, little is known about impact timing and types cancer on benefit...
Inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal that involves various organs, but has predilection for the urinary bladder in genitourinary tract. Given approximately half of all IMT cases have anaplastic lymphoma kinase (ALK) rearrangements, ALK inhibitor crizotinib suggested as promising treatment unresectable cases. No reports on neoadjuvant therapy locally advanced are available. We report case 17-year-old Japanese boy referred to our institution painful urination and...
Although eribulin is used to treat soft tissue sarcomas (STSs), treatment data for rare subtypes are limited. We conducted a post-marketing surveillance study assess safety and efficacy of in STS patients stratified by subtype.Japanese (n = 256) with advanced or metastatic receiving were monitored status, adverse events, diagnostic imaging, clinical outcomes at 3 months 1 year. Interim analysis was performed. Patients will be up 2 years.Interim included 3-month 255), imaging 226), 1-year...
Trabectedin is used as a treatment for advanced-stage soft tissue sarcomas (STSs), particularly liposarcoma and leiomyosarcoma. Aside from its direct effect on tumor cells, trabectedin can affect the immune system in microenvironment. This study aimed to evaluate whether inflammatory biomarkers predict efficacy STSs.
Abstract Introduction: Antibody-drug conjugates (ADCs) targeting trophoblast cell surface antigen 2 (TROP2), such as sacituzumab-govitecan and datopotamab-deruxtecan, have recently been developed. A preclinical study has reported the efficacy of anti-human epidermal growth factor receptor (HER2) TROP2 bispecific ADCs in treating HER2 co-expressing tumors, including HER2-low tumors various solid (Chengzhang Shang et al: AACR 2023). In this study, we aimed to evaluate expression by...
Purpose: To determine poor prognostic factors for patients with urachal carcinoma (UrC) undergoing radical surgery; identify candidates precision oncology, including adjuvant therapy; and improve survival outcome of this rare malignant disease. Materials Methods: We included 51 UrC who underwent or partial cystectomy at our institution between 1991 2023. Kaplan-Meier curves log-rank test were performed to estimate overall (OS) recurrence-free by applying the Ontario staging system. A Cox...
Abstract Background In this study, we aim to present the clinical outcomes of radiotherapy (RT) in pelvic lymph node‐positive prostate cancer (cN1) patients. We also analyze prognostic factors with focus on RT dose escalation metastatic nodes (LN). Methods retrospectively analyzed data from cN1 patients who were treated definitive and androgen deprivation therapy (ADT) between June 2004 February 2016. All received localized irradiation region whole pelvis irradiation. Some...
Objectives To determine the outcomes for elderly patients with de novo metastatic germ cell tumors and influence of patient age on adherence to standard chemotherapy. Methods A total 150 who were initially diagnosed treated at our institution between 2007 2021 included. Patients classified according three groups: aged <40, 40–49, ≥50 years. Clinicopathological features, first‐line chemotherapy, overall survival, disease‐free survival compared these groups. We also analyzed received...
To evaluate whether the extent of seminal vesicle invasion prostatic adenocarcinoma can stratify risk biochemical recurrence after radical prostatectomy.We carried out prostatectomy for 1309 patients with between 2006 and 2019; 135 (10.3%) had invasion. After excluding neo-/adjuvant therapy, we reviewed 105 patients. We analyzed correlation recurrence-free survival adjusted by various clinicopathological factors in multivariate analyses. Seminal was stratified into three groups; proximal...
eribulin, an anticancer agent that inhibits microtubule growth, along with trabectedin and pazopanib, has been approved for the treatment of advanced soft tissue sarcoma (STS). However, there no consensus on optimal second-line therapy among these three agents following failure doxorubicin. Recently, effects eribulin tumor microenvironment immunity have reported in breast cancer, peripheral blood immune markers also to be a predictor efficacy, though this remains unverified STS. We aimed...
Introduction In adults, rhabdomyosarcoma of the prostate is extremely rare and has an unfavorable prognosis. These patients frequently experience urinary obstruction, cysto‐prostatectomy a mainstay treatment for localized disease. contrast, strategies primary site metastatic disease remain controversial. To our knowledge, robot‐assisted surgery tumor not been reported. Case presentation A 26‐year‐old man complained dysuria. Magnetic resonance imaging showed enlarged computed tomography...